FBRX1:07 AMargenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipelinefortebiorx.com
FBRX8:00 AMFB102 Achieves Statistically Significant Improvement in Vitiligo at Week 24 After Completion of 12-Week Treatment PeriodTrial Resultsfortebiorx.com